JG
BPMC

Jefferies Group’s Blueprint Medicines BPMC Stock Holding History

Jefferies Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-46,700
Closed -$5.24M – 1641
2020
Q4 		$5.24M Sell
46,700
-33,600
-42% -$3.54M 0.04% 392
2020
Q3 		$7.44M Buy
80,300
+57,800
+257% +$4.45M 0.08% 205
2020
Q2 		$1.75K Buy
22,500
+7,300
+48% +$494K 0.02% 597
2020
Q1 		$889K Sell
15,200
-39,800
-72% -$2.56M 0.01% 1069
2019
Q4 		$4.41M Sell
55,000
-1,000
-2% -$74.9K 0.03% 581
2019
Q3 		$4.11M Buy
56,000
+50,000
+833% +$4.32M 0.03% 626
2019
Q2 		$566K Buy
+6,000
New +$495K ﹤0.01% 1610
2018
Q3 		– Sell
-30,000
Closed -$1.9M – 2412
2018
Q2 		$1.9M Buy
+30,000
New +$2.39M 0.01% 921

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jefferies Group's BPMC Position: Q1 2021 in Review

Jefferies Group sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 14,000 shares — an estimated $1.57M sold.

Jefferies Group first reported a position in BPMC in Q2 2018 and held it in 7 quarters. The position peaked at $2.43M in Q4 2019. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Jefferies Group reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Jefferies Group sold 14,000 Blueprint Medicines shares in Q1 2021, an estimated $1.57M.
  • Jefferies Group first reported a position in Blueprint Medicines in Q2 2018 and held it in 7 quarters.
  • Jefferies Group's Blueprint Medicines position peaked at $2.43M in Q4 2019.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.